Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Survodutide
Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist being developed by Boehringer Ingelheim.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range1.2 mcgWeeks 3-4
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range4.8 mcgWeeks 11-12
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range1.8 mgWeeks 5-6
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Survodutide
What published studies and recent community write-ups report about amounts, timing and course length. 5 clinical, 1 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical5 rows | |||||
| Phase 2 dose-finding trial in obesity387 adults aged 18-75 with a BMI of 27 or more and no diabetes | 0.6, 2.4, 3.6 or 4.8 mg maintenance | Once weekly | Subcutaneous | 46 weeks (20 weeks of escalation, then 26 weeks of maintenance)None; doses could be adjusted downward for gut tolerability during escalation | The Lancet Diabetes and Endocrinology (PubMed)2024 |
| Weight fell 6.2%, 12.5%, 13.2% and 14.9% at 46 weeks in the 0.6, 2.4, 3.6 and 4.8 mg groups against 2.8% on placebo, and those who actually stayed on 4.8 mg lost 18.7%. Only 60% of participants completed the 46 weeks, with gastrointestinal events in 75% of survodutide recipients, most of the dropouts occurring during the rapid two-weekly escalation. | |||||
| Phase 2 trial in type 2 diabetes413 adults with type 2 diabetes, HbA1c 7.0-10.0% and BMI 25-50, on metformin | Up to 0.3, 0.9, 1.8 or 2.7 mg once weekly, or 1.2 or 1.8 mg twice weekly | Once or twice weekly, escalated over 5-9 weeks | Subcutaneous | 16 weeksNone | Diabetologia (PubMed)2024 |
| HbA1c fell by 0.91 to 1.71 percentage points depending on dose, with 0.9 mg weekly matching open-label semaglutide 1 mg, and body weight fell by up to 8.7% in the 1.8 mg twice-weekly group versus 5.3% on semaglutide. Adverse events, mostly gastrointestinal, affected 78% of survodutide recipients against about 52% on placebo or semaglutide. | |||||
| Phase 2 trial in MASH with fibrosis293 adults with biopsy-confirmed MASH and stage F1 to F3 fibrosis | 2.4, 4.8 or 6.0 mg maintenance | Once weekly | Subcutaneous | 48 weeks (24 weeks of rapid escalation, then 24 weeks of maintenance)None | New England Journal of Medicine (PubMed)2024 |
| MASH improved without worsening fibrosis in 47%, 62% and 43% of the 2.4, 4.8 and 6.0 mg groups versus 14% on placebo, and liver fat fell by at least 30% in 57-67% of treated participants. Nausea (66%), diarrhea (49%) and vomiting (41%) were far more common than on placebo, while serious adverse events were similar at 8% and 7%. | |||||
| Phase 3 SYNCHRONIZE-1 (obesity without diabetes)725 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, without diabetes | Escalated to 3.6 mg or 6.0 mg | Once weekly | Subcutaneous | 76 weeksNone; a flexible escalation scheme allowed dose adjustment between weeks 16 and 32 for gut side effects | New England Journal of Medicine (PubMed)2026 |
| Weight change at 76 weeks was minus 12.2% and minus 13.0% for the 3.6 and 6.0 mg groups versus minus 5.4% on placebo by the treatment-regimen estimand (15.3% and 16.6% versus 3.2% by the efficacy estimand). Gastrointestinal events clustered in the escalation period and led 17.8% and 20.2% of the two survodutide groups to stop treatment, and resting heart rate rose by about 3 beats per minute. | |||||
| Phase 3 SYNCHRONIZE-2 (obesity with type 2 diabetes)755 adults with a BMI of 27 or more and type 2 diabetes | 3.6 mg or 6.0 mg | Once weekly | Subcutaneous | 76 weeksNone | Zealand Pharma via GlobeNewswire2026 |
| Weight fell by up to 13.1% versus 3.1% on placebo by the efficacy estimand, with HbA1c down by up to 1.21 percentage points from a 7.4% baseline, and both co-primary endpoints were met. Discontinuation for gastrointestinal adverse events was 18% on survodutide against 1.2% on placebo, which the sponsor attributes to the limited titration flexibility in this protocol. | |||||
| Preclinical1 row | |||||
| Preclinical diet-induced obese miceMale C57BL/6J mice fed a high-fat diet | 3, 10, 20 or 30 nmol/kg | Once daily | Subcutaneous | 30 daysNot applicable | Molecular Metabolism (PubMed Central)2022 |
| Daily dosing reduced body weight by up to 32% at day 28 at 30 nmol/kg, more than maximally effective semaglutide (25-27%), through both lower food intake and higher energy expenditure, with fat mass and liver triglycerides falling dose-dependently. Lean mass also fell at the two highest doses, and these rodent nmol/kg figures do not translate to human milligram doses. | |||||
| Community-reported3 rows | |||||
| Research-vial ladder in 4-week steps | 600 mcg, then 1.2, 1.8 and 2.4 mg, with optional 3.6 and 4.8 mg steps | Once weekly, stepping up every 4 weeks | Subcutaneous from a 10 mg vial reconstituted in 2 mL (5 mg/mL, 50 mcg per unit) | 16-24 weeks of escalation, then maintenanceNone described | Community resource2025 |
| A vendor-affiliated dosing site lays out a 600 mcg per step ladder that is slower than the two-weekly escalation used in phase 2, arguing that the slower climb reduces nausea and diarrhea. It presents the figures as reconstitution math anchored to trial ranges rather than guidance, and notes the compound is not approved anywhere. | |||||
| Trial-arm dosage chart with 6 and 10 mg vial math | 0.6, 2.4, 3.6 or 4.8 mg (phase 2 arms); 3.6 or 6.0 mg (phase 3 targets) | Once weekly | Subcutaneous from 6 mg or 10 mg research vials in 1-2 mL of bacteriostatic water | 46 weeks (phase 2) or 76 weeks (phase 3) as the reference coursesNone described | Community resource2026 |
| This 2026 guide reproduces the trial dose arms and their weight-loss results rather than inventing a schedule, and states that with no approved label there is no consumer dose to copy. Its planning tables count one vial per 4 weeks at common doses and one syringe per weekly injection. | |||||
| Reported user schedule versus registered titration | 0.3-0.6 mg start; maintenance targets of 3.6, 4.8 or 6.0 mg | Once weekly, stepped up every 2-4 weeks | Subcutaneous from 5, 10 or 20 mg vials | ContinuousNo consistent off period reported | Community resource2026 |
| A European reference site contrasts a registered kidney-disease trial ladder (0.3, 0.6, 1.2, 2.4 then 3.6 mg over 16 weeks, then 20 weeks at 3.6 mg) with user reports that disagree on whether to stop at 3.6, 4.8 or 6.0 mg. It stresses that 0.6 mg is 600 mcg and that a syringe unit copied from someone else's vial concentration delivers a different dose, citing FDA reports of five- to twentyfold self-dosing errors with compounded GLP-1 products. | |||||
How a course is commonly described
- Weeks 1-4: starting doseCommunity-reported
Trials started at 0.3-0.6 mg once weekly; community ladders copy the 0.6 mg start and hold it for 4 weeks. Nausea, vomiting, diarrhea and constipation begin in this period and are the main reason people stop.
- Weeks 5-20: escalationClinical
Phase 2 raised the dose every two weeks and reached maintenance by week 20, a pace that cost it 40% of participants before week 46. Phase 3 slowed the climb to 3.6 or 6.0 mg and added flexibility between weeks 16 and 32, yet 18-20% of participants still stopped for gut symptoms.
- Weeks 21-48: maintenanceClinical
Phase 2 held 0.6-4.8 mg for 26 weeks in obesity and 2.4-6.0 mg for 24 weeks in MASH, where the 4.8 mg arm had the best liver histology result and 6.0 mg added nothing. Weight was still falling at the end of both trials.
- Weeks 49-76: phase 3 endpointClinical
SYNCHRONIZE-1 measured its primary endpoint at week 76, with 13.0% weight loss on 6.0 mg by the treatment-regimen estimand and 16.6% among those who stayed on treatment. An MRI subgroup lost 34% of visceral fat and 63% of liver fat on 6.0 mg, alongside a 9.8% fall in lean body volume.
- StoppingCommunity-reported
No trial describes a planned break or taper, and user reports describe continuous dosing with no consistent off period. The phase 2 authors note that weight regain after stopping is the known weakness of this drug class, and no survodutide-specific discontinuation data have been published.
- Survodutide has no approved label, so even the phase 3 ladders are trial protocols rather than dosing recommendations. The highest maintenance dose any trial has used is 6.0 mg once weekly.
- Every trial lost a large share of participants to gastrointestinal effects during escalation, and the sponsor itself has said future trials will titrate more flexibly. Community ladders that slow the climb to 4 weeks per step have never been compared with the trial schedules.
- The C18 fatty diacid gives survodutide a half-life long enough for weekly dosing, which means each dose change takes several weeks to reach steady state. Vials sold online are unregulated, and the small milligram amounts make microgram-versus-milligram and unit-conversion errors the most likely way to be harmed.
Sources for this section (9)
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
- Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- Survodutide Once Weekly for the Treatment of Adults with Obesity
- Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial alongside significant improvements in glycemic control in people with type 2 diabetes
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Plus 3 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
How Survodutide is being studied to work
This process map organizes available educational context. Individual claims remain subject to source-level verification.
- 1
Mechanisms of Action
Research indicates that Survodutide works by binding to specific receptors in the brain and other tissues, which are involved in regulating hunger and energy expenditure. By activating these receptors, Survodutide helps reduce food intake, increase feelings of fullness, and boost energy expenditure,…
Overview
Survodutide (BI 456906) is an investigational once-weekly injectable peptide from Boehringer Ingelheim, licensed from Zealand Pharma, that activates both the glucagon receptor and the GLP-1 receptor. It is a 29-amino-acid analog of human glucagon with a protease-resistant residue at position 2 and a C18 fatty diacid on a linker at position 24 that binds albumin and stretches its half-life to allow weekly dosing. Phase 2 trials reported up to 14.9% weight loss at 46 weeks in obesity and histological improvement of MASH at 48 weeks, and the phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials published in 2026 reported 16.6% and 13.1% weight loss at 76 weeks among participants who stayed on treatment (13.0% in SYNCHRONIZE-1 once dropouts are counted). It has no approved label anywhere, so every schedule below is a trial protocol or a community copy of one, and vials sold online as survodutide are unregulated research chemicals.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Mechanisms of Action
Research indicates that Survodutide works by binding to specific receptors in the brain and other tissues, which are involved in regulating hunger and energy expenditure.…
- 2
Therapeutic Potential
The therapeutic potential of Survodutide lies in its ability to modulate key metabolic pathways. By mimicking the action of natural hormones, Survodutide can regulate appetite, enhance satiety, and promote weight loss.…
- 3
Research on Survodutide
Preclinical Studies Preclinical studies on Survodutide have provided promising insights into its potential benefits. In various animal models, Survodutide has been shown to significantly reduce body weight, regulate…
- 4
Clinical Trials
Survodutide is currently undergoing extensive clinical trials to assess its safety and efficacy in humans. Preliminary results from these trials have been encouraging, with participants experiencing significant weight…
- 5
Advancements in Metabolic Health
The future of Survodutide in the field of metabolic health looks promising. As ongoing research continues to validate its effectiveness and safety, Survodutide is poised to become a key player in the management of…
- 6
Innovation in Peptide-Based Therapies
The development of Survodutide represents a significant advancement in peptide-based therapies. Its unique mechanism of action and therapeutic benefits highlight the immense potential of peptides in addressing complex…
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Mechanisms of Action
Research indicates that Survodutide works by binding to specific receptors in the brain and other tissues, which are involved in regulating hunger and energy expenditure.…
- Not graded
Therapeutic Potential
The therapeutic potential of Survodutide lies in its ability to modulate key metabolic pathways. By mimicking the action of natural hormones, Survodutide can regulate appetite, enhance satiety, and promote weight loss.…
- Not graded
Research on Survodutide
Preclinical Studies Preclinical studies on Survodutide have provided promising insights into its potential benefits. In various animal models, Survodutide has been shown to significantly reduce body weight, regulate appetite, and improve metabolic health.…
Amounts recorded for Survodutide
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Weeks 3-4Sign in for schedule, duration and source context.1.2 mcg
- 2Weeks 11-12Sign in for schedule, duration and source context.4.8 mcg
- 3Weeks 5-6Sign in for schedule, duration and source context.1.8 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Also listed as
BI 456906, BI456906, Survodutide [INN], GTPL13383, EX-A7878, CAS 2805997-46-8 (listed on PubChem's second survodutide record, CID 171378821)
InChIKey
MEDXQFAHWBMVIM-YIUAJOCSSA-N
IUPAC name
18-[[4-[[2-[[(2R)-1-[[2-[[(2R)-1-[[2-[[2-[[(5R)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.